Abstract
Hormone replacement therapy (HRT) use declined sharply after mid-2002, when the Women’s Health Initiative trial reported an association between breast cancer occurrence and HRT. Hypothesized mechanism behind this association is that HRT promotes growth of pre-existing small tumors, leading to earlier tumor detection. We evaluated the impact of the sudden decline in HRT use on age distribution of breast cancer in Geneva. We included all incident breast cancer cases recorded from 1975 to 2006 at the Geneva cancer registry. We calculated mean annual incidence rates per 100,000 for 2 year periods for three age groups and assessed temporal changes by joinpoint regression. We compared age-specific incidence curves for different periods, reflecting different prevalence rates of HRT use. After increasing constantly between 1986 and 2002 among women aged 50–69 years [annual percent change (APC): +4.4, P < 0.0001], rates declined sharply after 2003 (APC: −6.0; P = 0.0264). Age-specific breast cancer rates changed dramatically with changes in prevalence of HRT use. During low HRT prevalence, breast cancer incidence increased progressively with age, when HRT prevalence was reaching its maximum (1995–2002), higher rates were seen in 60- to 64-year-old women, with a concomitant decrease in risk among elderly. After the sudden decline in HRT use, the incidence peak diminished significantly and incidence increased again with age. Following the abrupt decline in HRT use in Geneva, breast cancer incidence rates among post-menopausal women decreased considerably with striking changes in age-specific incidence rates before, during and after the peak in HRT prevalence.
Similar content being viewed by others
References
Beral V (2003) Million women study collaborators: breast cancer and hormone-replacement therapy in the million women study. Lancet 362(9382):419–427
(2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA 288(3):321–333
Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356(16):1670–1674
Katalinic A, Rawal R (2008) Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 107(3):427–430
Canfell K, Banks E, Clements M, Kang YJ, Moa A, Armstrong B, Beral V (2009) Sustained lower rates of HRT prescribing and breast cancer incidence in Australia since 2003. Breast Cancer Res Treat
Seradour B, Allemand H, Weill A, Ricordeau P (2009) Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from 2000 to 2006. Bull Cancer 96(4):E1–E6
Vankrunkelsven P, Kellen E, Lousbergh D, Cloes E, Op de Beeck L, Faes C, Bruckers L, Mertens R, Coebergh JW, Van Leeuwen FE, Buntinx F (2009) Reduction in hormone replacement therapy use and declining breast cancer incidence in the Belgian province of Limburg. Breast Cancer Res Treat
Morabia A, Costanza MC (2006) Recent reversal of trends in hormone therapy use in a European population. Menopause 13(1):111–115
Cancer incidence in five continents (2002) International Agency for Research on Cancer, vol VIII. IARC Scientific Publications no 155, Lyon
Verkooijen HM, Koot VC, Fioretta G, van der Heiden M, Schipper ME, Rapiti E, Peeters PH, Peterse JL, Bouchardy C (2008) Hormone replacement therapy, mammography screening and changing age-specific incidence rates of breast cancer: an ecological study comparing two European populations. Breast Cancer Res Treat 107(3):389–395
Observatoire suisse de la santé Obsan (2006) La santé en Suisse romande et au Tessin en 2002, 1 June 2009
Bouchardy C, Morabia A, Verkooijen HM, Fioretta G, Wespi Y, Schafer P (2006) Remarkable change in age-specific breast cancer incidence in the Swiss canton of Geneva and its possible relation with the use of hormone replacement therapy. BMC Cancer 6(1):78
Dietel M, Lewis MA, Shapiro S (2005) Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod 20(8):2052–2060
Bouchardy C (2002) Switzerland, Geneva. In: Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (eds) Cancer incidence in five continents, vol VIII. International Agency for Research on Cancer, Lyon, pp 448–449
National Cancer Institute (2007) Statistical research and applications. Joinpoint Regression Program, 1 May 2009
Glass AG, Lacey JV Jr, Carreon JD, Hoover RN (2007) Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 99(15):1152–1161
Reeves GK, Beral V, Green J, Gathani T, Bull D (2006) Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 7(11):910–918
Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL, Daling JR (2003) Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289(24):3254–3263
Li CI, Daling JR (2007) Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004. Cancer Epidemiol Biomarkers Prev 16(12):2773–2780
Verkooijen HM, Fioretta G, Vlastos G, Morabia A, Schubert H, Sappino AP, Pelte MF, Schafer P, Kurtz J, Bouchardy C (2003) Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland. Int J Cancer 104(6):778–781
Krieger N (2008) Hormone therapy and the rise and perhaps fall of US breast cancer incidence rates: critical reflections. Int J Epidemiol 37(3):627–637
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bouchardy, C., Usel, M., Verkooijen, H.M. et al. Changing pattern of age-specific breast cancer incidence in the Swiss canton of Geneva. Breast Cancer Res Treat 120, 519–523 (2010). https://doi.org/10.1007/s10549-009-0478-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-009-0478-y